Resumo

SORIANO GARCIA, Jorge L et al. Assessment on zoledronic acid use in patients with bone metastatic breast cancer. Rev cubana med [online]. 2010, vol.49, n.1, pp.33-64. ISSN 0034-7523.

OBJECTIVE: the biphosphonates are the cornerstone in the bone metastases treatment. In present paper the effectiveness and safety of the zoledronic acid (ZA) use in patients with bone metastatic breast cancer (MBC). METHODS: a descriptive and retrospective study was conducted in patients seen in Oncology Service of the «Hermanos Ameijeiras» Clinical Surgical Hospital from October, 2006 to December, 2007 with histological confirmation of MBC treated with ZA. Global survival and appearance time of new skeletal events (SE) was estimated using the Kaplan-Meier method. For means comparison we used the comparison test (Wilcoxon) in related samples. To assessment of pain response the analgesic visual scale (AVS). RESULTS: the survival means and the appearance time of some SE were of 33.82 months and of 27.72 months, respectively. The 50 % of patients showed AVS ³ 7 at treatment onset, and at 12 months, the 66.6 % had AVS =0 (p=0.021). In the 42.3 % was present a flu-like syndrome after the first infusion. There was not hematologic toxicity or significant variations of alkaline phosphatase values, LDH and creatinine. No case of renal failure. CONCLUSIONS: present paper is the first report in Cuba on use of ZA in cancer cases. The ZA effectiveness to reduce the SEs was demonstrated, as well as the appearance time of such events, the survival rise, the pain decrease and the quality of life increase. ZA has a good safety profile.

Palavras-chave : Biphosphonates; metastatic breast cancer; zoledronic acid; bone metastases.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )